Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Jacob T Brown; Jeffrey R Bishop; Katrin Sangkuhl; Erika L Nurmi; Daniel J Mueller; Jean C Dinh; Andrea Gaedigk; Teri E Klein; Kelly E Caudle; James T McCracken; Jose de Leon; J Steven Leeder

doi:10.1002/cpt.1409

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Clin Pharmacol Ther. 2019 Jul;106(1):94-102. doi: 10.1002/cpt.1409. Epub 2019 Apr 13.

Authors

Jacob T Brown¹, Jeffrey R Bishop², Katrin Sangkuhl³, Erika L Nurmi⁴, Daniel J Mueller^{5

6}, Jean C Dinh⁷, Andrea Gaedigk^{7

8}, Teri E Klein³, Kelly E Caudle⁹, James T McCracken⁴, Jose de Leon¹⁰, J Steven Leeder^{7

8}

Affiliations

¹ Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, Minnesota, USA.
² Department of Experimental and Clinical Pharmacology, College of Pharmacy, Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
³ Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
⁴ Division of Child and Adolescent Psychiatry, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA.
⁵ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
⁶ Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
⁷ Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
⁸ School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
⁹ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹⁰ University of Kentucky Mental Health Research Center, Eastern State Hospital, Lexington, Kentucky, USA.

Abstract

Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).

Publication types

Research Support, N.I.H., Extramural
Practice Guideline

MeSH terms

Adrenergic Uptake Inhibitors / administration & dosage
Adrenergic Uptake Inhibitors / adverse effects
Adrenergic Uptake Inhibitors / pharmacokinetics*
Adrenergic Uptake Inhibitors / therapeutic use*
Atomoxetine Hydrochloride / administration & dosage
Atomoxetine Hydrochloride / adverse effects
Atomoxetine Hydrochloride / pharmacokinetics*
Atomoxetine Hydrochloride / therapeutic use*
Attention Deficit Disorder with Hyperactivity / drug therapy*
Cytochrome P-450 CYP2D6 / genetics*
Dose-Response Relationship, Drug
Genetic Testing / methods
Genetic Testing / standards
Genotype
Humans
Pharmacogenetics

Substances

Adrenergic Uptake Inhibitors
Atomoxetine Hydrochloride
Cytochrome P-450 CYP2D6

Abstract

Publication types

MeSH terms

Substances

Grants and funding